BMYMP - Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)
2024-03-13 13:07:10 ET
Bristol-Myers Squibb Company (BMY)
Leerink Partners Global Biopharma Conference 2024 Conference Transcript
March 13, 2024, 10:00 AM ET
Executives
Samit Hirawat - Executive Vice President, Chief Medical Officer, Head, Development
Tim Power - Investor Relations
Janet Barth - Investor Relations
Analysts
Dave Risinger - Leerink Partners
Presentation
Dave Risinger
Great. So, good morning, everyone. My name is Dave Risinger. I cover diversified biopharmaceuticals for Leerink Partners and it’s very much my pleasure to welcome Bristol-Myers’ Chief Medical Officer, Samit Hirawat. And with him in the audience are Tim Power and Janet Barth in Investor Relations. We appreciate Samit joining us, taking the time out of his busy schedule to be with us here today.
Question-and-Answer Session
Q - Dave Risinger
So, I guess, it’d be great to have you kick off just by framing your vision for Bristol R&D including some of the company’s most substantial R&D projects that we should be focused on. And I know there are a lot of them, but a great -- it’d be great to have you just provide an initial framework.
Samit Hirawat
Sure. Thank you, Dave, and thank you, first of all, for having us here. It’s a great pleasure, because I can tell you, I’ve been in the industry for more than 20 years now and we’ve learned a lot about the biology of the disease. We understood the pathways and we continue to innovate. And when I think about the pipeline that Bristol has today, I truly believe that it is one of the most differentiated pipeline across the therapeutic areas that we are in....
Bristol-Myers Squibb Company (BMY) Management Presents at Leerink Partners Global Biopharma Conference 2024 Conference (Transcript)